Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Squamous cell carcinoma i… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus.

Artikel i vetenskaplig tidskrift
Författare Ulf Mattsson
Bengt Magnusson
Mats Jontell
Publicerad i Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
Volym 110
Nummer/häfte 1
Sidor e19-25
ISSN 1528-395X
Publiceringsår 2010
Publicerad vid Institutionen för odontologi
Sidor e19-25
Språk en
Länkar dx.doi.org/10.1016/j.tripleo.2010.0...
Ämnesord Administration, Buccal, Carcinoma, Squamous Cell, etiology, Clobetasol, administration & dosage, therapeutic use, Follow-Up Studies, Glucocorticoids, administration & dosage, therapeutic use, Humans, Immunosuppressive Agents, administration & dosage, therapeutic use, Lichen Planus, Oral, drug therapy, Male, Middle Aged, Mouth Neoplasms, etiology, Tacrolimus, administration & dosage, therapeutic use, Triamcinolone Acetonide, administration & dosage, therapeutic use
Ämneskategorier Mikrobiologi inom det medicinska området, Oral patologi och rättsodontologi

Sammanfattning

Oral lichen planus (OLP) is a chronic mucosal disorder of unclear etiology. The mainstay of therapy is topical use of steroids but other immuno-modulating therapies have also been tried. One such example is topical application of tacrolimus. Tacrolimus was in 2000 approved for treatment of atopic dermatitis, but in 2005 a boxed warning was included because of a potential risk of cancer development and for lack of long-term studies of the safety of the drug. The present study describes a patient who in 2003 was diagnosed with OLP and where treatment has included an intermittent use of tacrolimus. Five years after diagnosis, the patient developed a squamous cell carcinoma in the region where tacrolimus had been applied. The possible relationship between the use of tacrolimus and cancer development and rationale to include tacrolimus in OLP treatment is discussed.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?